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INTRODUCTION
Inflammatory markers including C-reactive 
protein (CRP), plasma viscosity (PV), and 
erythrocyte sedimentation rate (ESR) are 
long established tools for detection and 
monitoring of a variety of inflammatory 
conditions. Scandinavian studies in the 
1990s suggested inflammatory markers 
are measured in approximately 4% of GP 
consultations, for a range of indications, with 
44–47% for specific diagnostic purposes, 
27–33% for monitoring disease, and 14–28% 
for non-specific diagnostic purposes.1,2 
Testing rates have since significantly 
increased: CRP testing in the UK rising 
by 85.8% between 2005 and 2009.3 Large 
regional variations in testing rates have been 
noted, particularly with regard to PV.3 This 
could reflect different regional policies, but 
may indicate that GPs are uncertain about 
the appropriate use of these tests. There is 
also considerable inter-practice variation in 
GPs’ responses to abnormal inflammatory 
markers.2,4,5 Total costs of testing must be 
considerable; for example, over 120 000 
primary care requests for inflammatory 
markers were processed in 2014 at North 
Bristol NHS Trust, costing £177 000, for 
a population of 500 000 (P Virgo, personal 
communication, 2015). In 2006 overall 
annual pathology testing was estimated at 
£2.5 billion, nearly 4% of NHS expenditure.6
The classic conditions for which 
inflammatory markers are recommended 
as first line are polymyalgia rheumatica 
(PMR), giant cell arteritis,7,8 and myeloma.9 
Systematic reviews have also assessed the 
utility of CRP in diagnosing appendicitis,10 
neutropenic sepsis11,12 and serious infection 
in febrile children,13,14 joint infection,15,16 
chorioamnionitis,17 and several cancers 
in adults.18–23 These studies are mostly 
based in secondary care, so may be less 
applicable to primary care’s low disease 
prevalence settings. Primary care studies 
have demonstrated that point-of-care CRP 
testing for diagnosis of lower respiratory 
tract infections can reduce antibiotic 
prescribing and enhance patients’ and GPs’ 
confidence in prescribing decisions;24–27 
this is now incorporated into the National 
Institute for Health and Care Excellence 
(NICE) pneumonia guidelines.28
Another use of inflammatory markers 
is as a general indicator to differentiate 
between the presence and absence of 
disease. Evidence for this is based on small, 
old studies, mostly looking at ESR, which is 
now little used in clinical practice.29–32
When and why clinicians use 
inflammatory markers in primary care, 
including benefits and pitfalls of testing, 
have been little explored and qualitative 
studies are lacking. This study aimed to 
understand the real-life complexities of 
test use from a social science perspective, 
through qualitative interviews with GPs and 
nurse practitioners who order these tests.
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Abstract
Background 
Inflammatory markers can be helpful as part 
of the diagnostic workup for specific diseases 
or for monitoring disease activity. A third use is 
as a screening and/or triage tool to differentiate 
between the presence or absence of disease. 
Most research into inflammatory markers 
looks at diagnosis of specific diseases and 
comes from secondary care. Qualitative studies 
to explore when and why clinicians use these 
tests in primary care are lacking.
Aim
To identify clinicians’ approaches to 
inflammatory marker testing in primary care. 
Design and setting
Qualitative study with 26 GPs and nurse 
practitioners.
Method
Interviews were conducted using a semi-
structured topic guide. Clinicians reviewed 
recent cases of inflammatory marker testing 
in their pathology inbox. Interviews were 
audiorecorded and transcribed. Qualitative 
analysis was conducted by two of the authors.
Results
Clinicians are uncertain about the appropriate 
use of inflammatory markers and differ 
in their approach to testing patients with 
undifferentiated symptoms. Normal or 
significantly elevated inflammatory markers are 
seen as helpful, but mildly raised inflammatory 
markers in the context of non-specific 
symptoms are difficult to interpret. Clinicians 
describe a tension between not wanting to 
‘miss anything’ and, on the other hand, being 
wary of picking up borderline abnormalities 
that can lead to cascades of further tests. 
Diagnostic uncertainty is a common reason for 
inflammatory marker testing, with the aim to 
reassure; however, paradoxically, inconclusive 
results can generate a cycle of uncertainty and 
anxiety.
Conclusion
Further research is needed to define when 
inflammatory marker testing is useful in 
primary care and how to interpret results.
Keywords
acute-phase proteins; C-reactive protein; 
diagnosis; general practice; primary health 
care; qualitative research.
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METHOD
Recruitment
Thirty research-active primary care 
practices from a total of 55 practices in 
the Bristol Clinical Commissioning Group 
were invited by e-mail to participate via the 
e-bulletin of the West of England Clinical 
Research Network. Expressions of interest 
were received from 14 practices; of these 
10 participated. Purposive sampling was 
used to ensure a diversity of participants in 
terms of sex, years qualified, and practice 
role. In total 26 GPs and nurse practitioners 
were interviewed.
Interviews
Interviews were carried out by one of the 
authors and took place in participants’ 
GP practices. Participants were told that 
the interviewer is a GP registrar with an 
interest in test use in general practice. 
The interviewer had received training in 
qualitative research and was supervised by 
an experienced qualitative researcher. The 
first two interviews were treated as pilots but 
as data collection was successful they were 
subsequently added to the final dataset. 
Clinicians were paid £60 for participating. 
Ethical approval was obtained. Interviews 
were face to face, loosely structured around 
a topic guide with relevant areas explored in 
depth, and continued until data saturation 
was achieved. After briefly eliciting 
background information of clinicians’ 
training, current role, and experience of 
inflammatory marker testing, clinicians 
were asked to review their pathology inbox 
to identify and discuss anonymised recent 
cases of inflammatory marker testing to 
ensure the inclusion of real-life practice. 
A topic guide (Box 1) was used to provide 
prompts to ensure all areas were covered 
in each interview if they were not already 
spontaneously brought up. The topic guide 
evolved during the course of the study using 
information emerging in early interviews to 
develop further questions for exploration 
in subsequent interviews. The interviewer 
emphasised that the research process was 
non-judgemental, and that all interviews 
were confidential and anonymised, without 
names or practices linked to the comments. 
All interviews were audiorecorded using 
an encrypted device and lasted between 
23–48 minutes, with an average duration of 
32 minutes.
Analysis
The first two interviews were transcribed 
verbatim by the interviewer to increase 
familiarity with the data; thereafter an 
independent transcription service was 
used. Transcripts were checked, corrected, 
and anonymised by the interviewer prior 
to analysis. Analysis began when the first 
transcripts were available, so that data 
collection and analysis were conducted 
concurrently, with early interviews informing 
questions for subsequent interviews. Data 
were read and re-read to aid familiarity. The 
same researcher who carried out interviews 
led analysis, using NVivo. Analysis was 
thematic with key themes being developed 
and then compared across the dataset.33 
Two of the authors derived codes from four 
early transcripts, which were compared and 
refined in discussion to develop a single 
coding framework. The coding framework 
was applied to further transcripts and 
revised as necessary. Once coded, data were 
grouped into key categories or ‘themes’, 
which arose from the data in interaction 
with the original research questions using a 
grounded theory approach.34
RESULTS
Table 1 summarises the characteristics of 
the 26 participants. Twenty-two clinicians 
were recruited from 10 GP practices; four 
were locum GPs. Practices included a broad 
range of urban and suburban practices, with 
varying levels of socioeconomic deprivation; 
no rural practices were included. From 
the data four main themes emerged: 
reasons for inflammatory marker testing; 
interpretation and management of raised 
inflammatory markers; pitfalls of testing; 
and clinicians’ self-doubt about testing. 
Most of the data was elicited during 
discussions of clinical cases and relatively 
few prompts were needed.
Reasons for inflammatory marker testing
Inflammatory marker testing was 
performed for three main reason: diagnosis, 
monitoring, and ‘screening’. In diagnosis, 
clinicians were often trying to differentiate 
How this fits in
Inflammatory markers are used in primary 
care as part of the diagnostic workup 
for specific diseases or for monitoring 
disease activity. Clinicians also use them 
as a non-specific marker to differentiate 
between the presence or absence of 
disease in cases of diagnostic uncertainty. 
Interpretation of abnormal results in this 
context can be difficult and can lead to 
increased uncertainty and a cascade of 
further tests. Further research in primary 
care is needed to guide clinicians on when 
to test inflammatory markers and how to 
interpret abnormal results.
Box 1. Broad areas covered in 
topic guide
1.  Professional background, current role, 
experience of inflammatory marker testing.
2.  Review of recent cases of inflammatory 
marker testing using pathology inbox.
3.  Prompts (if necessary) around 
inflammatory marker testing: 
• reasons for testing;
• frequency of testing;
• expectations of tests;
• choice of test/batteries of tests used;
•  interpretation and management of 
results;
•  communication and explanations to 
patients;
• local guidelines or approaches;
•  other factors influencing testing rates 
— fear of litigation, patient attitudes, 
secondary care, point-of-care testing. 
Table 1. Characteristics of 
participants (n = 26)
Male Female
Role GP partner 6 6
Salaried GP 1 4
Locum GP 3 1
Nurse practitioner – 3
GP registrar – 2
Years 
experience
Newly qualified/
trainee (first 5 years 
of qualification)
3 6
Experienced 
(>5 years 
experience)
7 10
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minor illness from more serious conditions, 
for example, musculoskeletal joint 
pains versus inflammatory arthritis. The 
inflammatory marker alone was rarely 
diagnostic; with the possible exception of 
PMR:
‘PMR is a good example. Good story, raised 
viscosity, you’ve got your diagnosis in the 
bag and you feel happy doctor, because it’s 
very rare that anything like that happens.’ 
(Interview 11, male, locum GP, 16 years’ 
experience)
Sometimes inflammatory markers were 
part of the workup for referral, for example, 
to chronic fatigue clinic, memory clinic, or 
for patients potentially needing hospital 
admission:
‘CRP’s good for that, the orthopaedic 
surgeons respect it and other people do 
as well. If you want to get somebody in 
to hospital you say their CRP’s just gone 
from sort of 10 to 100, oh right, okay, I’ll 
see them.’ (Interview 2, male, GP partner, 
32 years’ experience)
Inflammatory markers were also used 
for monitoring response to treatment, for 
example, when reducing steroids in PMR, or 
at the request of secondary care colleagues:
‘There’s all the people who are on high-
risk drug monitoring, so all the people on 
methotrexate and all the rest of it, they have 
them done ad infinitum and we don’t fiddle 
with them because the hospital have said 
you should have some done.’ (Interview 7, 
male, GP partner, 7 years’ experience)
Finally, ‘screening’ was a term used by 
participants to mean the testing of patients 
with non-specific or undifferentiated 
symptoms without a clear diagnosis in mind. 
This could assist triage, or differentiate 
between the presence or absence of disease:
‘I’m fishing really. So it’s, a lot of our work 
is early presentation of undifferentiated 
disease and I get, essentially buying time 
I get very strongly reassured, rightly or 
wrongly, by negative inflammatory 
markers.’ (Interview 7, male, GP partner, 
7 years’ experience)
A clinician’s intuition of serious underlying 
pathology could trigger such use: 
‘Occasionally I may do it in someone where 
I’ve just got a slightly bad feeling about 
them, can’t put my finger on it but I’m kind 
of thinking, I do an inflammatory marker 
because it might help me potentially 
rule out, you know any nasty cancer or 
something that’s going on that I can’t quite 
put my finger on and if it comes up positive 
I’ll dig a little deeper, but if it comes back 
negative then I will be more comfortable 
with watching and waiting.’ (Interview 11, 
male, locum GP, 16 years’ experience)
Clinicians talked about a fear of ‘missing 
something’, especially something serious 
such as cancer, and used inflammatory 
markers to manage diagnostic uncertainty 
and to reassure themselves there was 
‘nothing serious going on’. Clinicians often 
expected normal results and used the test 
to help ‘rule out’ serious pathology:
‘So if we had a test that, a single blood test, 
that doctors could do which would reassure 
the patient there was nothing bloody wrong 
at all, then that would be a very popular test. 
We’ll have the “nothing wrong at all” test 
for you, sir … You know, all the other tests 
are, well, you might have this specifically 
wrong with you or you might have this … But 
the CRP is probably the closest thing that 
we’ve got to a “nothing wrong at all” test.’ 
(Interview 21, male, locum GP, 25 years’ 
experience)
However, clinicians’ opinions varied 
about using inflammatory markers for 
‘screening’, with some only using them 
when they had a specific diagnosis in mind. 
Interpretation and management of raised 
inflammatory markers
Normal or significantly elevated 
inflammatory markers were considered 
helpful and could usually be interpreted in 
the clinical context. However, mildly raised 
inflammatory markers in the context of 
non-specific symptoms were perceived as 
problematic:
‘So I think that if they’re very normal that’s 
good, if they’re very abnormal that’s helpful. 
I think that probably where the problem lies 
is if you get like a mildly raised viscosity and 
you wonder is that, how significant is that? 
And then if you requested it you’ve then got 
that and then what do you do about it …?’ 
(Interview 23, female, salaried GP, 1 year’s 
experience)
Most clinicians repeated a raised 
inflammatory marker result and then 
considered further additional tests, but 
were uncertain and differed about how 
long to wait and which tests to perform 
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next. Compared with other blood tests 
clinicians felt this was a particular 
challenge with inflammatory markers 
due to their non-specific nature. Very few 
cases of inflammatory markers revealed 
unexpected pathology that would otherwise 
have been missed. Rare examples were 
an unexpected case of tuberculosis and 
a retropharangeal abscess in someone 
who ‘just looked ill’; both had significantly 
elevated inflammatory markers. In contrast, 
cascades of further tests were frequent 
following a raised inflammatory marker in 
a hunt for pathology likened to ‘looking for 
a needle in a haystack’. If no cause could be 
found patients were sometimes referred to 
secondary care:
‘Then you think suddenly, well should I be 
looking further and further and further, but 
that could mean more and more random 
investigations until you get the point where 
you goes, oh, I’ll just do a whole body CT 
scan to see if anything pops up I suppose.’ 
(Interview 5, male, GP partner, 6 years’ 
experience)
Pitfalls with inflammatory marker testing
Clinicians gave several reasons to avoid 
inflammatory marker testing that stemmed 
from the non-specific nature of the tests. 
First, clinicians suggested they would not 
change management or that the tests 
were just ‘unhelpful’. Consequently, some 
emphasised the importance of considering 
why they were ordering the test and how 
they would manage the result before 
making the request. Without such careful 
consideration, borderline results could be 
difficult to interpret and potentially lead 
to uncertainty and anxiety. A particular 
challenge was dealing with a colleague’s 
blood results without knowledge of the 
patients’ symptoms and reasons for testing:
‘I sometimes think I shouldn’t have done 
that test because it’s just complicated 
things.’ (Interview 3, female, GP partner, 
20 years’ experience)
Interpreting abnormal results could also 
be difficult in patients with other potential 
reasons for raised inflammatory markers, 
for example, older patients and patients 
with comorbidities or obesity:
‘So well they’re surprisingly unhelpful in 
some ways, aren’t they? Over the years I’ve 
learned that very old people usually have 
a plasma viscosity that’s a little bit up … 
so you ignore the mildly raised viscosity in 
the older person and so you …  have to be 
more careful not to do it if it’s not going to 
influence your management. And the other 
people who have a raised plasma viscosity 
are obese people and maybe the people 
with high cholesterol as well.’ (Interview 9, 
female, partner, 23 years’ experience)
Finally, clinicians noted the workload 
generated by inflammatory marker testing, 
in particular with borderline results 
generating uncertainty and requiring 
further action:
‘Well, we were coming up with lots of mildly 
abnormal results, so mildly raised, and 
what does that mean? Is that okay? Can we 
live with that? Do we then have to repeat 
the test? … I kind of realised that I was 
becoming besieged by these PV results, 
which were, I didn’t really know what to do 
with.’ (Interview 22, female, salaried GP, 
10 years’ experience)
Clinicians’ self-doubt
Clinicians expressed uncertainty about 
whether they were doing the ‘right 
thing’ and felt it was an area that lacked 
teaching and evidence-based guidance. 
There was considerable variation in which 
inflammatory marker to use according 
to clinicians’ training and experience. In 
general, clinicians considered plasma 
viscosity better for ‘screening’ and CRP 
more useful for diagnosis or monitoring 
of infections or specific inflammatory 
conditions. Some used both CRP and 
viscosity but felt they were ‘probably not 
supposed to’:
‘Having had this discussion it’s kind of 
left me with questions and definitely 
thinking should I, shouldn’t I be doing that? ‘ 
(Interview 25, female, salaried GP, 7 years’ 
experience)
‘With GPs, a lot of things are oh well it is 
what I do and it’s what I have always done 
and erm it seems to work, so yeah I’ll just 
do it a bit more … so what we end up doing 
is kind of making it up, so if you have got 
somebody who has got slightly abnormal 
CRP, when do you re-check it? There’s no 
guidelines, so you think to yourself well 
you know perhaps it will be 2 weeks or 
maybe 4 weeks or maybe when their chest 
infection has gone? ‘ (Interview 19, female, 
GP partner, 13 years’ experience)
Nurse practitioners used inflammatory 
markers less frequently, both because they 
tended to see minor illnesses and because 
they held a perception that inflammatory 
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markers were ‘a bit out of my sphere of 
competence’ unless with GP guidance. 
Consequently, they had fewer concerns 
about the uncertainty of test results and 
management of abnormal results could be 
‘handed over’ to GP colleagues for follow-up. 
Cycle of uncertainty and anxiety with 
inflammatory marker testing
As demonstrated, diagnostic uncertainty 
was a common reason for inflammatory 
marker testing, as a ‘screening’ tool for 
serious disease. Although the aim of testing 
was often ‘for reassurance’, inconclusive 
or borderline results could paradoxically 
generate increased uncertainty and anxiety 
(Figure 1). This led to a tension between 
clinicians wanting to make sure they were 
not ‘missing something’, and conversely 
not wanting to generate unhelpful or 
uninterpretable results. This tension was 
particularly apparent with inflammatory 
markers compared with other blood tests:
‘I think there is a bit of a mystique about 
the usefulness of CRP testing, and we all 
know what an FBC and U&Es, and it’s very 
well defined, isn’t it? But the implications 
and the usage of CRP is very vague, it’s a 
kind of, no one ever taught us about the 
practicalities of ordering a CRP, and that’s 
one of the issues really.’ (Interview 4, male, 
GP partner, 17 years’ experience)
DISCUSSION
Summary
As far as we are aware this is the first 
qualitative study into the use of inflammatory 
markers in primary care. Clinicians used 
inflammatory markers for diagnosis and 
monitoring, yet differed particularly in 
their approach to ‘screening’ patients with 
undifferentiated symptoms. Normal or 
significantly raised inflammatory markers 
were considered helpful but borderline 
abnormalities were difficult to interpret 
due to the non-specific nature of the tests. 
Clinicians described a tension between not 
wanting to ‘miss anything’ and, on the other 
hand, being wary of picking up borderline 
abnormalities leading to further tests. This 
tension was compounded by clinicians’ 
uncertainty about whether they were doing 
the ‘right thing’. Diagnostic uncertainty 
was a common reason for inflammatory 
marker testing aiming to reassure; however, 
paradoxically, inconclusive results could 
generate a cycle of increased uncertainty 
and anxiety.
This difficulty interpreting abnormal 
results and the consequent uncertainty is 
a particular characteristic of inflammatory 
markers due to their non-specific nature; 
however, it is unlikely to be a unique problem. 
Similar difficulties of interpreting borderline 
abnormalities could be of relevance for a 
range of blood tests.
Strengths and limitations
A strength of this study was the use of real-life 
cases, which ensured data were grounded 
in daily clinical practice, thereby reducing 
the chances of cognitive biases or doctors 
presenting an idealised practice of what they 
think they ‘should’ do. Interviews were carried 
out by a GP registrar, allowing interviewees 
to feel comfortable discussing cases with a 
fellow clinician with shared understanding. 
However, this could influence the reflexivity 
of the interviewer who had their own a priori 
experiences of inflammatory marker testing 
and an interest in the uncertainty and lack 
of evidence-based guidelines in this area. 
Although it was emphasised that interviews 
were non-judgemental, some clinicians may 
have felt uncomfortable discussing areas of 
clinical practice where they felt uncertain, 
defensive, or deficient, and may therefore 
have reinterpreted their diagnostic argument 
for testing from intuitive to more rational 
Figure 1. Cycle of uncertainty and anxiety in 
inflammatory marker testing. Uncertainty about 
diagnosis can lead to increased testing rates. This 
increases the chance of borderline test results, 
which may cause more uncertainty and anxiety. 
B
or
de
rl
in
e 
te
st
 re
su
lts Uncertainty about diagnosis
Increased testing rate
s
‘I think that GPs can underestimate the 
power of their own reassurance and 
sometimes actually what you’re doing 
is creating anxiety with the patients. So 
a doctor picks up on the patient‘s 
anxiety, develops their own anxiety, 
chucks that back on the patient who 
then gets more anxious.’ (Interview 9, 
female, partner, 23 years’ experience)
‘Well, if they’re, if it’s very 
slightly raised, but nothing 
obviously wrong with the 
patient, just makes you worry 
but you can’t do anything other 
than worry and review and retest 
maybe.’ (Interview 11, male 
locum, 16 years’ experience)
‘Well I tend to use them, erm this is 
going to sound awful, if I am not 
sure what is going on, so and I am 
trying to sort out you know is this 
serious.’ (Interview 19, female, 
partner, 13 years’ experience)
‘I think that it probably, the more uncertain 
you are the more it tends to increase your 
blood testing rates.’ (Interview 6, male, 
partner, 25 years’ experience)
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thoughts. Similarly, clinicians who were less 
confident about inflammatory marker testing 
may have declined to take part. This could 
imply that ‘real-life’ testing is more haphazard 
and less logical than presented here. Fewer 
nurse practitioners were sampled than 
doctors because it became evident in the 
study that they rarely requested inflammatory 
markers or managed results. No rural 
practices participated, where clinicians may 
have slightly different approaches to blood 
testing, for example, if laboratory services 
are less accessible. Interviews were only 
undertaken with clinicians; in future work, 
patients’ perspectives would be useful.
Comparison with existing literature
Despite little evidence supporting the use 
of inflammatory markers for screening or 
triage35 it was observed that many GPs use 
these tests for patients with undifferentiated 
symptoms. This mirrors research among 
Dutch GPs reporting that unexplained 
complaints are positively associated with 
test ordering behaviour (odds ratio 2.4, 95% 
confidence interval = 1.2 to 5.3).36 Patients 
with unexplained complaints presenting with 
fatigue and longer duration of symptoms are 
more likely to have blood tests done.37
Some GPs avoided inflammatory 
markers for non-specific purposes in case 
results were unhelpful. This concurs with 
previous research on ESR showing that 
generally, when GPs use inflammatory 
markers for non-specific purposes, results 
are afterwards seen as being of little or 
no clinical value.1 Previous questionnaire 
studies looking at blood testing generally 
have shown that abnormal test results are 
common, even when tests are requested 
for reassurance or to exclude disease with 
low pre-test probability, suggesting GPs 
should be cautious about using blood tests 
for ‘screening’ or non-specific purposes.38 
Other studies focusing on tests in general 
have shown that, although doctors may 
be reassured by negative testing when no 
disease is suspected,39 normal diagnostic 
tests make little difference to the level of 
patient reassurance.40,41 Furthermore, this 
study has shown that borderline results 
may actually increase anxiety, rather than 
reassure, and lead to further testing, a pitfall 
which Deyo called the cascade effect of 
medical technology.42 Sah and colleagues 
explored this issue of inconclusive tests, 
coining the term ‘‘investigation momentum’: 
the concept that the psychological uncertainty 
experienced after an inconclusive test 
leads to additional testing in the ‘relentless 
pursuit to resolve uncertainty’.43 Although 
some clinicians in this study perceived that 
abnormal test results could increase patient 
anxiety and lead to further cascade testing, 
the frequency of ‘cascade testing’ and 
patients’ views are under-researched.
Implications for research and practice
This study highlights a problem with 
inflammatory marker testing, which may 
ring true for practising clinicians but is rarely 
discussed in research literature. Clinicians 
should consider the potential pitfalls of 
inflammatory marker testing and think 
about how they will use the results before 
requesting the tests. Estimates from a UK 
Department of Health-commissioned review 
of pathology services in 2008 calculated that 
approximately 25% of pathology tests were 
unnecessary, representing considerable 
waste.6 An Academy of Medical Royal 
Colleges report has called for doctors to 
take responsibility for cutting waste in a 
finite system, with overuse of diagnostic tests 
being one of three core areas of suggested 
focus.44 More recently, the potential harm to 
patients has also been highlighted, with the 
initiative ‘Choosing Wisely’45 aiming to identify 
areas not supported by evidence, not free 
from harm, or not truly necessary. 
Inflammatory markers, performed without 
clear clinical indication, may potentially be 
such an unnecessary intervention. However, 
the opposite problem, of under-testing 
and missed diagnosis, is also a concern, 
and in fact both may coexist. In particular, 
much of the UK’s poor record in cancer 
outcomes is blamed on diagnostic delays. 
One factor that has received little attention 
is raised inflammatory markers that have 
been shown to be of relevance in breast,18,19 
lung,20 colon,21 ovarian,22 and urological 
cancers.23 Further research is needed to 
help clinicians interpret raised inflammatory 
markers, as previous studies usually 
start with a single disease state, often in 
secondary care settings, and estimate the 
probability of raised inflammatory markers. 
However, clinicians start with a test result 
and need to know the predictive probability of 
a wide range of possible diseases, including 
risk of cancer. Research is also needed to 
quantify the benefits and harms of using 
inflammatory markers for patients with 
undifferentiated symptoms as a tool to try to 
‘rule out’ serious pathology.
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